Education
About Us
Working with TipRanks
Follow Us
ALK-abello A/S Class B (AKBLF)
OTHER OTC:AKBLF
AKBLF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$17.25 - $28.00
Previous CloseN/A
Volume1.00
Average Volume (3M)0.00
Market Cap
$5.09B
Enterprise Value$35.94B
Total Cash (Recent Filing)kr418.00M
Total Debt (Recent Filing)kr45.00M
Price to Earnings (P/E)42.4
Beta0.89
Next Earnings
May 06, 2025EPS Estimate
0.21Last Dividend Ex-Date
Mar 16, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)0.53
Shares Outstanding202,567,200
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.62
Price to Book (P/B)N/A
Price to Sales (P/S)4.09
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$28.27Price Target Upside28.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
ALK-abello News
PremiumCompany Announcements
ALK-abello A/S: Record Growth and Market Challenges
PremiumCompany Announcements
ALK-Abelló Reports Record Growth and Strong Outlook
PremiumCompany Announcements
ALK-Abelló A/S Reports Strong Q3 Growth
---
Options Prices
Currently, No data available
---
Ownership Overview
0.03% Insiders
3.57% Mutual Funds
― Other Institutional Investors
92.14% Public Companies and
Individual Investors
AKBLF FAQ
What was ALK-abello A/S Class B’s price range in the past 12 months?
ALK-abello A/S Class B lowest stock price was $17.25 and its highest was $28.00 in the past 12 months.
What is ALK-abello A/S Class B’s market cap?
ALK-abello A/S Class B’s market cap is $5.09B.
When is ALK-abello A/S Class B’s upcoming earnings report date?
ALK-abello A/S Class B’s upcoming earnings report date is May 06, 2025 which is in 12 days.
How were ALK-abello A/S Class B’s earnings last quarter?
ALK-abello A/S Class B released its earnings results on Feb 19, 2025. The company reported $0.122 earnings per share for the quarter, missing the consensus estimate of $0.145 by -$0.023.
Is ALK-abello A/S Class B overvalued?
According to Wall Street analysts ALK-abello A/S Class B’s price is currently Undervalued.
Does ALK-abello A/S Class B pay dividends?
ALK-abello A/S Class B pays a Notavailable dividend of $0.038 which represents an annual dividend yield of N/A. See more information on ALK-abello A/S Class B dividends here
What is ALK-abello A/S Class B’s EPS estimate?
ALK-abello A/S Class B’s EPS estimate is 0.21.
How many shares outstanding does ALK-abello A/S Class B have?
ALK-abello A/S Class B has 202,567,200 shares outstanding.
What happened to ALK-abello A/S Class B’s price movement after its last earnings report?
ALK-abello A/S Class B reported an EPS of $0.122 in its last earnings report, missing expectations of $0.145. Following the earnings report the stock price went up 5.355%.
Which hedge fund is a major shareholder of ALK-abello A/S Class B?
Currently, no hedge funds are holding shares in AKBLF
---
Company Description
ALK-abello A/S Class B
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company offers GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX for the treatment of allergic rhinitis; and ACARIZAX for treating allergic rhinitis and allergic asthma. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.
---
AKBLF Company Deck
---
AKBLF Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a strong year for ALK with record revenue growth and positive execution of strategic initiatives, particularly in Europe. However, challenges in North America and international markets, especially China, alongside negative free cash flow, reflect areas of concern.Read More>---
AKBLF Stock 12 Month Forecast
Average Price Target
$28.27
▲(28.38% Upside)
Technical Analysis
Dynavax
―
Inovio Pharmaceuticals
―
Aclaris Therapeutics
―
Emergent Biosolutions
―
Novartis
―
Bristol Myers
―
Best Analysts Covering AKBLF
1 Year
1 Year Success Rate
0/1 ratings generated profit
1 Year Average Return
-0.90%
upgraded a buy rating 3 months ago
Copying Benjamin Jackson CFA's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -0.90% per trade.
---